A poison pill — formally a shareholder rights plan — is a board-adopted charter-level defense that triggers when any acquirer crosses an ownership threshold, typically 10 to 20 percent: every shareholder except the acquirer receives rights to buy additional shares at a steep discount, instantly diluting the raider's stake and making the takeover uneconomic. The device was invented by lawyer Martin Lipton in 1982, upheld as lawful board conduct in Delaware's 1985 Unocal and Moran decisions, and rendered nearly extinct by the 2000s shareholder movement — until it roared back in 2020–2021 as a defense against activist accumulation, with a dozen S&P 500 companies adopting plans in 2021 alone.
The Daily News 24 publishes information, not investment or policy advice. This explainer covers corporate-defense mechanics.
How does the dilution work?
The board distributes rights attached to existing shares, exercisable only after a trigger. In the classic flip-in form, once the raider crosses the threshold, each right lets other holders buy stock at half price — a 15 percent raider can watch its stake diluted to a fraction as everyone else doubles up cheaply. In the flip-over form, rights convert into acquirer shares at a discount after a merger, punishing the buyer directly. The raider, excluded by the plan's terms, is the only one who does not get to buy at the discount it created. No litigation is required; the arithmetic executes itself.
What are the modern variants?
The 2020s revival modified the classic form. The NOL pill protects net-operating-loss carryforwards by deterring any 5-percent holder whose accumulation could limit the tax asset under IRS rules. The vague-activist pill — used by notable 2020-2021 adoptions — sets triggers below conventional thresholds to slow rapid accumulation by activists coordinating informally. And event-driven pills emerged in 2022 against special-purpose acquisition companies, deterring SPAC structures that threatened control through share issuance. Each variant keeps the same core: the board controls the trigger and the redemption price, typically a cent, letting it pull the pill the moment a negotiated deal appears.
Why did pills die and come back?
Death by norms and litigation: institutional shareholders and proxy advisers treat pills as entrenchment, and Delaware courts review them under enhanced scrutiny where a board deploys one against a coercive threat it cannot show. By the 2010s, most large companies let pills lapse — a hostile takeover without one became theoretically possible, though staggered boards and Delaware precedent still favored defenses. The revival's driver was the activist era: accumulation-then-campaign plays by funds building stakes through swaps and cash-settled derivatives — positions below disclosure thresholds — made boards re-armor. Notably, Elon Musk's 2022 Twitter stake accumulation, crossing 5 percent without prompt disclosure, renewed attention to exactly this gap.
What can shareholders do about a pill?
Vote it down where charter rules require renewal, pressure through proxy campaigns, or litigate in Delaware on breach of fiduciary duty — the Unocal standard asks whether the defense was reasonable relative to a demonstrated threat. Pills adopted without shareholder ratification typically expire within a year under modern board practice, a self-imposed discipline that answers the entrenchment objection while keeping the emergency brake.
How should readers read a pill adoption?
The trigger threshold tells the story: a 20 percent trigger is heritage defense against a hostile bid; a 5 percent or acquisition-disclosure trigger signals fear of a specific accumulator the board suspects but will not name. Either way, the message is the same — the board saw something worth diluting.
For more context, read Why Companies Go Private in Leveraged Buyouts.
For more context, read dividend yield.
For more context, read Why Companies Split Their Stock.